Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.

This is written in the approval document.

Reimbursement

ODMS

Citation

Atezolizumab 1680mg Monotherapy - 28 Day, 2020, version number 1, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6399/593_v10a_Atezolizumab_1680mg_Monotherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) EGFR Somatic variants Non-Small Cell Lung Cancer Atezolizumab
HSE (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab